Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
Keywords
Abstract
Dates
| Last Verified: | 05/31/2020 |
| First Submitted: | 03/10/2020 |
| Estimated Enrollment Submitted: | 03/10/2020 |
| First Posted: | 03/15/2020 |
| Last Update Submitted: | 06/14/2020 |
| Last Update Posted: | 06/16/2020 |
| Actual Study Start Date: | 09/30/2020 |
| Estimated Primary Completion Date: | 09/30/2021 |
| Estimated Study Completion Date: | 09/30/2022 |
Condition or disease
Intervention/treatment
Drug: 2LEBV® / 2LXFS®
Drug: Placebo
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: 2LEBV® / 2LXFS® 6 months of treatment | Drug: 2LEBV® / 2LXFS® The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day. |
| Placebo Comparator: Placebo 6 months of treatment | Drug: Placebo The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day. |
Eligibility Criteria
| Ages Eligible for Study | 12 Years To 12 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Pré-Inclusion Criteria: - Patients, male or female, aged 12 years and older, - Patient with fatigue for 1 month or more, - Patient with at least two other symptoms among the following: Long-lasting exhaustion even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina, conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly, visual disorders, memory disorders, attention deficit disorders, sleep disorders, gastrointestinal disorders, breathing disorders, cardiovascular disorders. - Patient (and/or parents if necessary) agrees to perform serology for the study, - Patient (and/or parents if necessary) agrees to perform lymphocyte typing for the study during the pre-inclusion visit, - Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study, - Signature of the Informed Consent Form by the patient (and/or parents if necessary). Inclusion Criteria: - Patient who have a positive serology for EBV (IgG and/or IgM positive). Exclusion Criteria: - Patient who have received any treatment with the 2LEBV® or 2LXFS®, - Patients who have received any homeopathic treatment in the previous 2 months prior to the study, - Patients under immunosuppressive treatment, - Patient undergoing treatment for psychiatric disorders, - Patients having received immunotherapy or micro-immunotherapy during the last 3 months, - Patients with known lactose intolerance, - Pregnant or breastfeeding women, - Patients who participated in a clinical study in the previous 2-months period, - Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study, - Patients with severe immunodeficiency disease requiring long term treatment (*) or patients under chemotherapy or radiotherapy, - Patients under homeopathic or phytotherapy treatment, - Patients addicted to or using recreational drugs, - Patient under guardianship and/or curatorship, (*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer. |
Outcome
Primary Outcome Measures
1. Measure of the general fatigue scale of the Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire at the end of the treatment. [6 months]
Secondary Outcome Measures
1. Comparison of the efficacy of the treatment on physical fatigue, reduced activity, reduced motivation and mental fatigue scales on the MFI-20 questionnaire between the 2LEBV® or the 2LXFS®/2LEBV® group versus the placebo group [6 months]
2. Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group. [3 months]
3. Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group. [12 months]
4. Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group. [6 months]
5. Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group. [12 months]
6. Comparison of the evolution of the lymphocytes typing between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group. [12 months]
7. Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug. [6 months]
8. Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group. [3 months]
